Enzymatic Deracemization of (R,S)-Ibuprofen Ester via Lipase-catalyzed Membrane Reactor
MetadataShow full item record
Ibuprofen (isobutyl-propanoic-phenolic acid) is a chiral drug which essentially well-known for its analgesic, antipyretic and anti-inflammatory effects. In the present work, an enzymatic membrane reactor (EMR) has been developed for the production of optically pure (S)-ibuprofen acid. The EMR is equipped with a multi-tubular fixed bed racemization unit to enhance the enzymatic deracemization of (R,S)-ibuprofen ester. Several process parameters such as enzyme loading, racemization catalyst loading, reaction temperature, buffer pH as well as the flow rate were investigated. These experimental results were then compared with the proposed process model. It was found that the experimental data were in good agreement with the theoretical results. The optimum condition of the lipase-catalyzed dynamic kinetic resolution (DKR) using the EMR could give 96-98% conversion with 97-99% of product enantiomeric excess (eep).
Showing items related by title, author, creator and subject.
Kamaruddin, A.; Uzir, M.; Gonawan, F.; Lau, John (2015)© Springer International Publishing Switzerland 2015. The optical purity of non-steriodal anti-inflammatory drugs (NSAIDs) is one of the concerns in pharmaceutical industries, since the enantiomers demonstrate distinct ...
Effect of co-solvent addition on the reaction kinetics of the lipase-catalyzed resolution of ibuprofen esterGonawan, Fadzil; Lau, John; Kamaruddin, Azlina; Uzir, Mohamad (2013)BACKGROUND: The addition of co-solvent is not limited to enhancing the catalytic rate, it could also assist in situ racemization in the dynamic kinetic resolution of racemic compounds by increasing the reactivity of the ...
Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albuminYamasaki, K.; Hyodo, S.; Taguchi, K.; Nishi, K.; Yamaotsu, N.; Hirono, S.; Chuang, Victor; Seo, H.; Maruyama, T.; Otagiri, M. (2017)A wide variety of drugs bind to human serum albumin (HSA) at its two principal sites, namely site I and site II. A number of reports indicate that drug binding to these two binding sites are not completely independent, ...